Leland Stanford Junior University

Cellgate, Inc.

Lumen Therapeutics, LLC

Kai Pharmaceuticals, Inc.

Other

Celonova Biosciences, Inc.

Jonathan B Rothbard

Paul A Wender

Thorsten A Kirschberg

Lalitha V S Sista

P Leo McGrane

Edgar George Engleman

C Garrison Fathman

Paul Leo McGrane

Erik Kreider

Gary K Schoolnik

John P Cooke

Lawrence Steinman

Richard L Klein

Hong M Moulton

Rima McLeod

Kamal El Bissati

Lee Robert Wright

Robert C Robbins

Ernest J Mui

John C Bravman

Theodore C Jessop

Erin T Pelkey

Kanaka Pattabiraman

Christopher L VanDeusen

Dimitrios Pantelidis

Jon D Moulton

William Witola

Murray H Kown

Shiro Uemura

Garrison C Fathman

Bo Shiun Lai

Leo P McGrane

The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of specific peptides derived from HSPB5, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease.

Small heat shock proteins and active fragments thereof as a therapy for inflammation and ischemia

This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.

Compositions and methods for treating diseases

This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including into and across ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.

Compositions and methods for enhancing drug delivery across and into ocular tissues

This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.

Compositions and methods for enhancing drug delivery across and into epithelial tissues

Pharmaceutical formulations of antisense peptide-conjugated phosphorodiamidate morpholino olgomers and methods of use for treatment of apicomplexan infections are disclosed. The invention is particularly directed to treatment ofinfections.

Conjugate constructs, delivery, and use for treatment of disease

This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including into and across ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length (for example, SEQ ID NO:86).

Implantable medical devices employing a sol-gel composition coatings that functions as a bioactive material reservoir, and the use of sol-gel composition coatings for improved adhesion of organic and inorganic substrates are disclosed.

Bioactive material delivery systems comprising sol-gel compositions

The present invention provides compositions and methods for enhancing transport of biologically active compounds across biological membranes and across and into animal epithelial or endothelial tissues. The composition includes a biologically active agent and a transport moiety. The transport moiety includes a structure selected from the group consisting of (ZYZ)Z, (ZY)Z, (ZYY)Z and (ZYYY)Z. Subunit 'Z' is L-arginine or D-arginine, and subunit 'Y' is an amino acid that does not comprise an amidino or guanidino moiety. Subscript &#x201c;n&#x201d; is an integer ranging from 2 to 10. The method for enhancing transport involves the administration of the aforementioned composition.

Transporters comprising spaced arginine moieties

This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including into and across ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length (SEQ ID NO:86).

Transport reagents and conjugates of therapeutic agents linked to transport reagents are described. In particular, the transport reagents have a plurality of guanidinium moieties that are either contiguous or spaced along a backbone, but are sufficiently removed from the backbone via tethers, to allow their interaction with a cell or tissue surface, leading to uptake of the therapeutic agent.

Guanidinium transport reagents and conjugates

This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length (SEQ ID NO:50).

This invention provides compositions and methods for enhancing delivery of glucocorticoids and ascomycins such as hydrocortisone, cyclosporin and FK506 across into and across one or more layers of the skin for the treatment of psoriasis and other inflammatory diseases of the skin.

Growing community of inventors

Cupertino, CA, United States of America

Jonathan B Rothbard